RxDoctor Payments Data

Neeraja Yedlapati, MD

Cardiovascular Disease · Memphis, TNNPI 1942538335

Payments from drug & device makers

$3,108in general payments, 2019–2025

Across 132 payments — averaging $23.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$630
  • Boehringer Ingelheim$312
  • Boston Scientific$305
  • E.r. Squibb & Sons, L.L.C.$256
  • Novartis$253
  • AstraZeneca$194
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,108100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,108 in reported general payments places this provider in the 55th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$430,739
Medicare patients
1,414
Services billed
5,192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban321$297,848
EntrestoSacubitril/Valsartan190$232,203
JardianceEmpagliflozin174$203,713
FarxigaDapagliflozin Propanediol97$100,828
Repatha SureclickEvolocumab78$63,014
XareltoRivaroxaban62$54,402
Repatha SyringeEvolocumab33$33,296
BrilintaTicagrelor29$20,422
VascepaIcosapent Ethyl23$11,458
Praluent PenAlirocumab23$11,079
Rosuvastatin Calcium563$6,895
Icosapent Ethyl17$5,370
Carvedilol617$4,881
Nifedipine ErNifedipine100$4,614
Atorvastatin Calcium313$3,488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$54$297,848321 claims
NovartisEntresto$253$232,203190 claims
Boehringer IngelheimJardiance$312$203,713174 claims
AstraZenecaFarxiga, Brilinta$194$121,250126 claims
Johnson & JohnsonXarelto$97$54,40262 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →